on imaging studies. Hepatic steatosis, defined histologically as greater than 5 % of hepatocytes with macrovesicular fat accumulation, correlates with decreased hepatic attenuation seen on computed tomography (CT) [1] . Unenhanced abdominal CT has a sensitivity of 91 % and specificity of 99 % for the diagnosis of hepatic steatosis [2] . While CT scan can identify the presence of steatosis, it cannot distinguish between the various etiologies of steatosis, including alcoholic liver disease, NAFLD, nonalcoholic steatohepatitis (NASH) and hepatitis C virus (HCV) infection, nor can it evaluate for the presence of hepatic fibrosis.
NAFLD represents the most frequent etiology of hepatic steatosis [3] . The diagnosis of NAFLD requires evidence of hepatic fat accumulation by imaging or histology and the exclusion of secondary causes of steatosis including hepatitis C infection and alcohol use [4] . Once a diagnosis of NAFLD is confirmed, it is important to distinguish between steatosis which is associated with low risk of liver disease progression and NASH which confers an increased risk of liver-related mortality, cirrhosis, and hepatocellular carcinoma (HCC) [5] . The American Association for the Study of Liver Disease (AASLD) recommends that individuals with incidentally identified hepatic steatosis be assessed for abnormal liver biochemistries, signs, and symptoms of liver disease, as well as for the presence of the metabolic syndrome and other causes of steatosis including medication and alcohol use [4] . In addition, scoring systems such as the NAFLD fibrosis score can help determine an individual's risk of NASH and advanced fibrosis and when combined with imaging can identify patients at risk for advanced liver disease and in whom further evaluation is needed [6] . The identification of fatty liver on imaging is often an important first step in bringing patients to clinical attention.
There are limited published data concerning primary care physician (PCP) evaluation and management of patients with NAFLD. A recent survey of PCPs in Wisconsin revealed that 88 % of surveyed physicians reported encountering at least one patient with NAFLD in the preceding year and 58 % indicated that a lack of confidence in their knowledge of NAFLD was a significant barrier to management [7] . Given these findings and the critical role of PCPs in the initial management of this prevalent condition, we sought to characterize the PCP-initiated evaluation of individuals with incidentally identified hepatic steatosis on CT scan. We hypothesized that hepatic steatosis identified on imaging would be infrequently documented in the medical record. Further, we hypothesized that evaluation for secondary causes of NAFLD and referral for further evaluation would be infrequent, even among individuals at high risk for advanced fibrosis and cirrhosis.
Subjects and Methods

Subjects and Study Design
The radiology database at the Massachusetts General Hospital was queried for renal stone protocol CTs (unenhanced CT) and hematuria protocol CTs (enhanced and unenhanced CT) performed from January 2008 to October 2011. CT scans performed for other indications including abdominal pain were excluded to eliminate indication bias. Imaging reports that included terms ''steatosis,'' ''fatty infiltration,'' and ''fatty liver'' were selected. Patients less than 18 years of age and greater than 85 years of age at the time of image acquisition were excluded. Patients' electronic medical records were searched using a comprehensive search tool, Queriable Patient Inference Dossier (QPID), for terms ''steatosis,'' ''NAFLD,'' ''NASH,'' ''fatty liver,'' ''hepatic steatosis,'' ''cirrhosis,'' ''hepatitis C,'' ''HCV,'' ''HCC,'' ''HCC,'' ''Wilson's disease,'' ''celiac disease,'' ''autoimmune hepatitis,'' ''hepatitis B (HCV),'' ''HBV,'' and ''hemochromatosis.'' The QPID search tool searches all text present within the electronic medical record including all patient care notes, radiology, and laboratory reports. Patients with previously identified steatosis, chronic HCV infection, chronic HBV infection, autoimmune hepatitis, hemochromatosis, cirrhosis, HCC, Wilson's disease, celiac disease, pregnancy, or metastatic cancer at time of imaging study were excluded. In order to ensure longitudinal follow-up in our health-care system, patients without PCPs in our health system or without at least one PCP follow-up appointment within 14 months of imaging were excluded from the study.
Measurements
Patients' medical records were searched to assess baseline data spanning up to 36 months prior to the date of the imaging study demonstrating hepatic steatosis. Baseline data included gender; liver function tests (LFTs); markers of synthetic function including prothrombin time, INR, and albumin; complete blood cell count; glycosylated hemoglobin (HGBA1C); fasting glucose; lipid panel; ferritin; weight; height; body mass index (BMI); HCV antibody; HBV surface antigen; diagnosis of hypertension; hyperlipidemia; and diabetes mellitus. For alcohol use screening, search terms ''ETOH,'' ''alcohol,'' and ''drinks'' were used. If multiple sets of labs or other data were obtained during the 36 months prior to imaging study (for example, BMI recorded three times in the 36 month period prior to imaging study), the most recent values prior to the imaging study were recorded. A 36-month period was chosen to capture results from infrequently ordered tests (HCV antibody, HBV surface antibody, HBV surface antigen, HGBA1C, etc.). Medical records were searched for use of medications known to induce steatosis including amiodarone, tamoxifen, corticosteroids, or methotrexate at any point during the preceding 36 months prior to imaging.
CT scan reports were reviewed to assess location of documentation of hepatic steatosis and categorized as reporting either in body of report alone or within both the body and the impression section of report. The impression portion of radiology reports at our institution consists of numbered statements summarizing key findings in the report (Table 1 ).
All PCP documentation was individually reviewed in the 14 months after performance of imaging study for documentation of hepatic steatosis; alcohol use screening; gastroenterology/hepatology referral; laboratory testing including aminotransferase, glucose, and insulin levels; and use of clinical scoring system to assess for risk of fibrosis such as NAFLD fibrosis score or BARD score. Pathology reports within 14 months after imaging date were reviewed to assess for liver biopsy results. If sufficient data were available, the investigators calculated the NAFLD fibrosis score using an online calculator (http:// nafldscore.com/) [6] .
Statistical Analysis
Characteristics of patients' whose physicians-documented hepatic steatosis after imaging study were compared to patients' whose physicians did not document hepatic steatosis using two-tailed Fisher's exact test for categorical variables or two-sample t test for continuous variables. The percentage of patients with PCP-documented steatosis among patients where steatosis was reported within body versus impression of radiology reports were compared using two-tailed Fisher's exact test. Logistic regression was used to assess predictors of PCP documentation. Twotailed p values of less than 0.05 were considered significant. STATA (StataCorp) was used for analyses.
Results
Baseline Characteristics
Two hundred and ninety-three patients with incidentally identified hepatic steatosis on CT scans were identified. Ultimately, 127 patients (43 %) were included in the study (96 patients excluded for no primary care follow-up, 56 patients excluded for prior liver disease, and 14 patients excluded for metastatic cancer). The records of eighty-four unique PCPs were reviewed, and CT scans were read by one of 29 radiologists. Most patients were obese (68 %) with 33.8 % of patients with BMI [35 and 13.4 % with BMI [40. (Table 2 ) There were high baseline rates of hypertension (60 %), hyperlipidemia (60 %), and diabetes (27 %). Alcohol use was minimal with 47 % reporting no 
Primary Care Physician-Initiated Evaluation of Hepatic Steatosis
In the 14-month period following an initial radiology report of hepatic steatosis on CT, only 29 patients (22.8 %) had PCP documentation of steatosis in the medical record. This included direct communications with patients, adding steatosis to a patient's problem list or documenting steatosis in a progress note. No patients were referred to a gastroenterologist or hepatologist for further evaluation, and no patients had a liver biopsy performed in the followup period. In addition, no PCPs documented the application of clinical scores such as the NAFLD fibrosis score or BARD score to assess patients' risk for advanced hepatic fibrosis. We evaluated patient characteristics that might be associated with PCP documentation of incidentally identified hepatic steatosis (Table 3) . BMI, gender, age, diabetes, hypertension, hyperlipidemia, and heavy alcohol consumption ([14 drinks per week) were not significantly associated with PCP documentation of hepatic steatosis. There was a trend toward an association between baselineelevated aminotransferase levels and PCP documentation of steatosis, though this did not reach statistical significance (p = 0.08). However, the placement of the findings of steatosis in the radiology report did have a significant impact on PCP documentation. When reporting of hepatic steatosis was included in both the body of radiographic reports and in the ''impression'' section, PCPs were significantly more likely to document presence of hepatic steatosis in patients' medical records than if the finding was included only in the body of the report (30.1 vs. 9.1 %, p = 0.007; Table 3 ).
We sought to characterize the impact of PCP documentation of hepatic steatosis on their subsequent evaluation of the etiology of the steatosis. Patients whose physicians documented steatosis in the medical record were more likely to have aminotransferase levels checked (96.5 vs. 77.5 %, p = 0.025), and undergo alcohol use (89.6 vs. 66.3 %, p = 0.018), and hepatitis C screening (20.6 vs. 2.0 %, p = 0.0018; Table 4 ). There were no differences between groups in rates of screening for dyslipidemia, insulin resistance, or ferritin levels.
There was sufficient data within the medical record at time of CT scan to calculate the NAFLD fibrosis score in 105 patients (82.6 %). Forty-nine patients (38.5 %) had NAFLD fibrosis scores less than -1.455 corresponding to a low risk for advanced fibrosis, 42 patients (32.8 %) had indeterminate scores between -1.455 and 0.676, and 14 patients (11 %) had scores greater than 0.676 corresponding to a high risk of advanced fibrosis. Only two of 14 patients with a high-risk NAFLD fibrosis score had hepatic steatosis documented within the medical record, and none were referred for further evaluation or liver biopsy.
Discussion
Our study demonstrates that hepatic steatosis identified incidentally on imaging studies was infrequently documented by PCPs. In addition, the present study found that when steatosis was documented, higher rates of screening for abnormal aminotransferase levels as well as higher levels of screening for hepatitis C and alcohol use disorders occurred. This finding suggests that when incidentally identified steatosis is recognized, it results in a change in practice and a more comprehensive evaluation for possible liver disease. In addition, we found that prominent placement of the finding of hepatic steatosis in radiographic reports, specifically in the ''impression'' section that serves to summarize important findings, was associated with a significant increase in documentation. This finding suggests that many PCPs may be aware of the importance of steatosis as a clinical problem but that a lack of emphasis on this finding in radiographic reports may limit their awareness of the new diagnosis. The addition of hepatic steatosis to the impression section or conclusions of radiographic reports may improve the recognition and evaluation of steatosis.
To address the impact of PCP recognition of incidentally identified steatosis on clinical outcomes, we assessed NAFLD fibrosis scores for all individuals where data were available. The NAFLD fibrosis score incorporates age, BMI, presence of hyperglycemia or diabetes, aminotransferase levels, platelet count, and albumin level and can be easily utilized in the primary care setting. Further, the NAFLD fibrosis score is validated to identify NAFLD patients at risk for advanced fibrosis [8] . Recently, Angulo et al. [9] demonstrated that the NAFLD fibrosis score was a strong predictor of liver-related complications and death in a large retrospective study of patients with NAFLD and a mean follow-up of 104.8 months. By applying the NAFLD fibrosis score to the study patient population, we identified 14 patients (11 %) at high risk for advanced fibrosis and cirrhosis who may also be an increased risk for HCC. These high-risk patients warrant additional evaluation and more intensive follow-up including referral to a specialist, evaluation for liver biopsy, and consideration of HCC screening. Surprisingly, none of the patients in our study were referred for specialist evaluation or for liver biopsy during our study time period.
This low rate poses several potential problems in the care of these patients. First, with high population mobility and transitions in care of providers, there is potential for Our study had several limitations. First, the CT scans in the present study may have been ordered by providers other than the primary provider, and the primary provider may not have been aware of the CT scan findings. To address this, our group is currently studying the impact of an alert system, sending such incident findings to primary physicians to assure they are notified of important findings even when they are not the ordering provider. It is possible that providers did recommend additional testing for patients found to have steatosis, and this was performed at other facilities or not completed by the patient. However, the lack of any mention of the incidentally discovered steatosis in the medical record argues against this. Additionally, this was a single-center study and may reflect unique institutional practices and biases. Future studies including multiple centers will be needed to confirm these findings and to determine the impact of changing radiologic reporting practices on recognition of steatosis. In addition, the limited duration of our study does not allow for the assessment of important clinical outcomes such as progression to cirrhosis or liver-related complications. To estimate this, we calculated the NAFLD fibrosis score which is a predictor of the presence of advanced fibrosis and liver-related mortality. However, longer-term studies would be needed to determine whose PCP recognition and evaluation of incidentally identified steatosis would change clinical outcomes.
In conclusion, documentation of incidentally indentified radiographic steatosis by PCPs at our institution was limited. Inclusion of steatosis in the impression section of radiographic reports was associated with higher rates of PCP documentation. Further, documentation of steatosis was associated with higher rates of aminotransferase testing, HCV, and alcohol screening. Clinical scoring systems, specialist referrals, and liver biopsy were infrequently utilized in evaluation of these patients at this study institution. Future educational efforts for PCPs should focus on use of clinical scoring systems, timing of specialist referral, and strategies for screening for secondary causes of steatosis. Furthermore, radiology departments should include hepatic steatosis within the impression of reports when identified to improve PCP recognition of this common condition.
